A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT ID: NCT06046729
Last Updated: 2025-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
352 participants
INTERVENTIONAL
2023-10-23
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
NCT04493502
Hidradenitis Suppurativa Phase 2b Study of Izokibep
NCT05355805
Etanercept in Hidradenitis Suppurativa
NCT00329823
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06411899
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06411379
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eltrekibart Dose 1
Eltrekibart will be given subcutaneously (SC).
Eltrekibart
Administered SC
Eltrekibart Dose 2
Eltrekibart will be given SC.
Eltrekibart
Administered SC
Eltrekibart Dose 3
Eltrekibart will be given SC.
Eltrekibart
Administered SC
Placebo
Placebo will be given.
Placebo
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eltrekibart
Administered SC
Placebo
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
* Have an (abscess plus inflammatory nodule) count of at least 5.
* Agree to use topical antiseptics daily.
* Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
Exclusion Criteria
* Have had surgical treatment for HS in the last 4 weeks before randomization.
* Have an active skin disease or condition, that could interfere with the assessment of HS.
* Have a current or recent acute, active infection.
* Are immunocompromised.
* Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Dermatology Specialists
Phoenix, Arizona, United States
Saguaro Dermatology Associates, LLC - Probity - PPDS
Phoenix, Arizona, United States
Arkansas Research Trials, LLC
North Little Rock, Arkansas, United States
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas, United States
First OC Dermatology Research Inc
Fountain Valley, California, United States
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Dermatology Institute and Skin Care Center
Santa Monica, California, United States
University of Connecticut
Farmington, Connecticut, United States
Direct Helpers Research Center
Hialeah, Florida, United States
University of Miami
Miami, Florida, United States
Skin Research of South Florida
Miami, Florida, United States
ForCare Clinical Research
Tampa, Florida, United States
Alliance Clinical Research of Tampa
Tampa, Florida, United States
Olympian Clinical Research
Tampa, Florida, United States
Advanced Medical Research, PC
Sandy Springs, Georgia, United States
NorthShore Medical Group Dermatology - Skokie
Skokie, Illinois, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Equity Medical - Bowling Green
Bowling Green, Kentucky, United States
Derm Research LLC
Louisville, Kentucky, United States
Care Access-Marriottsville
Marriottsville, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Revival Research Institute - Troy
Troy, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
Skin Specialists, P.C
Omaha, Nebraska, United States
ActivMed Practices & Research, Inc.
Portsmouth, New Hampshire, United States
Darst Dermatology
Charlotte, North Carolina, United States
Dermatology Specialists of Charlotte
Charlotte, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Apex Clinical Research Center
Mayfield Heights, Ohio, United States
DermDox Centers for Dermatology
Camp Hill, Pennsylvania, United States
DermDox Dermatology Centers
Sugarloaf, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Columbia Dermatology & Aesthetics
Columbia, South Carolina, United States
International Clinical Research - Tennessee (IC Research)
Murfreesboro, Tennessee, United States
Advanced Research Experts
Nashville, Tennessee, United States
Modern Research Associates
Dallas, Texas, United States
North Texas Clinical Research
Frisco, Texas, United States
Jordan Valley Dermatology Center
South Jordan, Utah, United States
Dermatology Specialists of Spokane
Spokane, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
East Sydney Doctors
Darlinghurst, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Sinclair Dermatology - East Melbourne
East Melbourne, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Fremantle Dermatology
Fremantle, Western Australia, Australia
Holdsworth House Medical Practice
Sydney, , Australia
Beacon Dermatology
Calgary, Alberta, Canada
Alberta Dermasurgery Centre
Edmonton, Alberta, Canada
Wiseman Dermatology Research Inc.
Winnipeg, Manitoba, Canada
Brunswick Dermatology Center
Fredericton, New Brunswick, Canada
Simcoderm Medical & Surgical Dermatology Centre
Barrie, Ontario, Canada
DermEffects - Probity - PPDS
London, Ontario, Canada
Center de Recherche St Louis
Québec, Quebec, Canada
Hautklinik Erlangen
Erlangen, Bavaria, Germany
Hautarztpraxis Mahlow
Blankenfelde-Mahlow, Brandenburg, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Hesse, Germany
Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB) - St. Josef-Hospital
Bochum, North Rhine-Westphalia, Germany
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, Germany
Universitätsklinikum Münster - Albert Schweitzer Campus
Münster, Westfalen, Germany
Hautzentrum Friedrichshain - Dermatologie
Berlin, , Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, , Germany
Hospital of Venereal and Skin Diseases A.Syggros
Athens, Attica, Greece
University General Hospital of Heraklion Loc. 1
Heraklion, Irakleío, Greece
Papageorgiou General Hospital of Thessaloniki
Thessaloniki, Thessaloníki, Greece
Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska
Wroclaw, Lower Silesian Voivodeship, Poland
Wro Medica
Wroclaw, Lower Silesian Voivodeship, Poland
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, Pomeranian Voivodeship, Poland
Klinika Badawcza Centrum Badan Klinicznych Wojciech Brzezicki
Malbork, Pomeranian Voivodeship, Poland
Centrum Medyczne Pratia Katowice
Katowice, Silesian Voivodeship, Poland
Dermoklinika-Centrum Medyczne s.c
Lodz, Łódź Voivodeship, Poland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I7P-MC-DSAF
Identifier Type: OTHER
Identifier Source: secondary_id
2023-505608-43-00
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1292-6255
Identifier Type: OTHER
Identifier Source: secondary_id
18518
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.